BridgeBio Oncology Therapeutics Inc. (BBOT) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.60
↓-36% vs avg
5yr avg: 0.94
30Y Low0.9·High0.9
ROE
↑
-44.7%
↓+28% vs avg
5yr avg: -61.7%
30Y Low-79%·High-45%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BBOT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BridgeBio Oncology Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $185M | $390M | $175M | — | — | — |
| Enterprise Value | $-186140260 | $19M | $173M | — | — | — |
| P/E Ratio → | -1.83 | — | 22.83 | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.60 | 0.95 | 0.93 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BBOT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
BBOT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -44.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -44.7% | -44.7% | -78.7% | — | — | — |
| ROA | -41.7% | -41.7% | -76.3% | -27100.6% | -2.4% | -30.1% |
| ROIC | -96.3% | -96.3% | -64.9% | -350050.4% | -13.3% | — |
| ROCE | -48.0% | -48.0% | -83.3% | — | — | — |
BBOT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $374M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.90 | -0.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($374M) exceeds total debt ($3M)
BBOT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BridgeBio Oncology Therapeutics Inc.'s current ratio of 12.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 10.40x to 12.14x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 12.14 | 12.14 | 10.40 | — | — | — |
| Quick Ratio | 12.14 | 12.14 | 10.40 | — | — | — |
| Cash Ratio | 22.81 | 22.81 | 9.05 | — | — | — |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
BBOT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BridgeBio Oncology Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 4.4% | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $31M | $17M | $20M | $20M | $20M |
Peer Comparison
Compare BBOT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BBOTYou | $185M | -1.8 | — | — | — | — | -44.7% | -96.3% | — |
 BBIO | $13B | -17.8 | — | — | 94.4% | -113.3% | — | -524.0% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 AUPH | $2B | 7.3 | 19.0 | 14.8 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See BBOT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBOT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BBOT vs BBIO
Side-by-side business, growth, and profitability comparison vs BridgeBio Pharma, Inc..
Start ComparisonBBOT — Frequently Asked Questions
Quick answers to the most common questions about buying BBOT stock.
What is BridgeBio Oncology Therapeutics Inc.'s P/E ratio?
BridgeBio Oncology Therapeutics Inc.'s current P/E ratio is -1.8x. The historical average is 22.8x.
What is BridgeBio Oncology Therapeutics Inc.'s ROE?
BridgeBio Oncology Therapeutics Inc.'s return on equity (ROE) is -44.7%. The historical average is -61.7%.
Is BBOT stock overvalued?
Based on historical data, BridgeBio Oncology Therapeutics Inc. is trading at a P/E of -1.8x. Compare with industry peers and growth rates for a complete picture.